...
首页> 外文期刊>Bone marrow transplantation >Frequency of CD4+ FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD
【24h】

Frequency of CD4+ FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD

机译:HLA不匹配的异基因造血SCT后CD4 + FOXP3 +调节性T细胞在早期阶段的频率可预测急性GVHD的发生

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Acute GVHD (aGVHD) is a major obstacle to allogeneic hematopoietic SCT (alloHSCT). Although it is thought that aGVHD is initiated in secondary lymphoid organs at a very early stage of alloHSCT, whether CD4+ FOXP3 + regulatory T-cells (Tregs) have an impact on aGVHD development during this period remains unclear. Here, we measured Tregs in peripheral blood as early as possible after HLA-mismatched alloHSCT, and assessed the incidence of aGVHD. Flow cytometric analyses revealed that at the second week after HSCT, patients with aGVHD had significantly (P=0.018) lower Treg:CD4+ T-cell ratios than those without aGVHD. As these differences were seen before the development of aGVHD, these ratios can predict the incidence of aGVHD. The cumulative incidence of aGVHD in patients with ratios of 9% was significantly higher than that in patients with ratios of ≥9% (P=0.0082, log-rank test). Additionally, the specific ratio of Tregs:CD4+ T-cells was the most significant value among all other possible lymphocyte-associated ratios and absolute cell counts. These findings suggest that the ratio of Tregs:CD4+ T-cells at the second week post HLA-mismatched alloHSCT might be a potent predictor of aGVHD in these patients. The practical efficacy of this finding should be verified in further interventional studies.
机译:急性GVHD(aGVHD)是异基因造血SCT(alloHSCT)的主要障碍。尽管认为aGVHD是在alloHSCT的早期阶段在次级淋巴器官中引发的,但尚不清楚在此期间CD4 + FOXP3 +调节性T细胞(Treg)是否对aGVHD的发育有影响。在这里,我们在HLA不匹配的alloHSCT之后尽早测量了外周血中的Treg,并评估了aGVHD的发生率。流式细胞仪分析显示,在HSCT后第二周,aGVHD患者的Treg:CD4 + T细胞比率显着(P = 0.018)低于无aGVHD的患者。由于这些差异是在aGVHD发生之前就已经看到的,因此这些比率可以预测aGVHD的发生率。比率<9%的患者aGVHD的累积发生率显着高于比率≥9%的患者(P = 0.0082,对数秩检验)。此外,在所有其他可能的淋巴细胞相关比率和绝对细胞计数中,Tregs:CD4 + T细胞的比值是最显着的值。这些发现表明,在HLA不匹配的allHSCT后第二周,Tregs:CD4 + T细胞的比例可能是这些患者中aGVHD的有效预测指标。这一发现的实际疗效应在进一步的干预研究中得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号